Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06355804 · ClinicalTrials.gov registry record · NA

Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis

A NA study of Multiple Sclerosis, sponsored by University of Illinois at Chicago.

Active
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT06355804: Active NA study of Multiple Sclerosis, sponsored by University of Illinois at Chicago.

NCT06355804 is a NA study of Multiple Sclerosis that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 52 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06355804, a NA study of Multiple Sclerosis, is active but no longer recruiting, sponsored by University of Illinois at Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years). Specific Aim 1: To evaluate the changes in self-report and device-measured physical activity after the 16-week remotely delivered physical activity behavior change intervention compared with a control condition (i.e., waitlist control) in persons who have diagnosed with MS within the past two years. The investigators hypothesize that the 16-week behavior change intervention will yield greater improvements in physical activity levels than the control condition immediately after the intervention. Specific Aim 2: To investigate the efficacy of the 16-week, remotely delivered physical activity behavior change intervention compared with the control condition for improvements in fatigue, depression, anxiety, and QoL in persons newly diagnosed with MS. The investigators hypothesize that there will be beneficial effects on the symptoms and QoL outcomes immediately after the physical activity intervention compared with minimal changes in the control condition.

Primary Outcome

Godin Leisure-Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in physical activity behavior.

Conditions Studied

Interventions

  • BEHAVIORAL Physical activity condition
  • BEHAVIORAL Waitlist condition

Study Locations (1)

Illinois

  • University of Illinois Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-04-29
Est. Completion 2026-12-01
Phase NA
University of Illinois at Chicago

430 total trials

What the registry record for NCT06355804 still lists

NCT06355804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Physical activity condition is the first listed.

NCT06355804 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06355804 about?

NCT06355804 is a clinical study titled "Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis". The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years). Specific Aim 1: To evaluate the chang...

What is the current status of trial NCT06355804?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2024-04-29. Estimated completion is 2026-12-01.

What conditions does trial NCT06355804 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06355804?

The interventions under investigation include: Physical activity condition (BEHAVIORAL), Waitlist condition (BEHAVIORAL).

Who is sponsoring clinical trial NCT06355804?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06355804 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06355804's enrollment target sits among peer trials

52 173rd of 315 higher than 141 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06355804, the US trial registry maintained by the National Library of Medicine. NCT06355804 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.